Sign In
Buy EDTXF
$0.99
-0.0010 (-0.101%)
At Close: Jul 31, 2026
Spectral Medical Receives US$3 Million From Vantive
07:30am, Monday, 25'th Aug 2025
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and
Spectral Medical Announces Second Quarter and Provides Corporate Update
07:30am, Friday, 08'th Aug 2025
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
03:10pm, Friday, 04'th Jul 2025
TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
10:59am, Friday, 06'th Jun 2025
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock,
Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
08:00am, Friday, 16'th May 2025
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic s
Spectral Medical Announces First Quarter and Provides Corporate Update
07:30am, Friday, 09'th May 2025
TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic s
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
07:00am, Wednesday, 07'th May 2025
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • �
Spectral Medical Announces Fourth Quarter and Fiscal 2024 Results and Provides Corporate Update
07:30am, Thursday, 27'th Mar 2025
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic
Spectral Medical Provides November Tigris Trial Update
08:00am, Monday, 02'nd Dec 2024
• 136 patients enrolled • Company to host Tigris Trial Update Call December 16, 2024 TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TS
Spectral Medical Announces Third Quarter Results and Provides Corporate Update
08:00am, Friday, 08'th Nov 2024
Tigris Trial Enrollment at 135 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment
Spectral Medical Provides October Tigris Trial Update
08:00am, Monday, 04'th Nov 2024
• 135 patients enrolled TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic opti
Spectral Medical Announces Second Quarter Results and Provides Corporate Update
08:00am, Friday, 09'th Aug 2024
Tigris Trial Enrollment Reaches 126 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spe
Spectral Medical Provides July Tigris Trial Update
08:00am, Thursday, 01'st Aug 2024
• 125 patients enrolled• Record July patient enrollment to start the second half of 2024
Spectral Medical Inc. Announces Change to Auditor
04:00pm, Thursday, 11'th Jul 2024
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock,
